These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22273457)

  • 1. Clinical outcomes of intracoronary eptifibatide bolus only versus intracoronary bolus and intravenous infusion of eptifibatide in primary percutaneous coronary intervention.
    Soon D; Ho HH; Loh KK; Ooi YW; Foo D; Jafary FH; Ong PJ
    Acute Card Care; 2012 Mar; 14(1):42-4. PubMed ID: 22273457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction.
    Pinto DS; Kirtane AJ; Ruocco NA; Deibele AJ; Shui A; Buros J; Murphy SA; Gibson CM
    Am J Cardiol; 2005 Dec; 96(11):1494-7. PubMed ID: 16310428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina.
    Deibele AJ; Kirtane AJ; Pinto DS; Lucca MJ; Neva C; Shui A; Murphy SA; Tcheng JE; Gibson CM
    J Thromb Thrombolysis; 2006 Aug; 22(1):47-50. PubMed ID: 16786232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 1-year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein IIb/IIIa Inhibitors.
    Kassaian SE; Fathi Y; Lotfi-Tokaldany M; Salarifar M; Alidoosti M; Haji-Zeinali AM; Aghajani H; Amirzadegan A; Nozari Y; Mortazavi SH; Jalali A; Saroukhani S
    Crit Pathw Cardiol; 2016 Sep; 15(3):89-94. PubMed ID: 27465002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
    Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
    Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study.
    Hassan W; Al-Sergani H; Al Buraiki J; Dunn B; Al Turki F; Akhras N; Elshaer F; Nawaz M; Kharabsheh S; ElKum N
    Am Heart J; 2007 Aug; 154(2):345-51. PubMed ID: 17643587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
    Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
    Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Kırma C; Erkol A; Pala S; Oduncu V; Dündar C; İzgi A; Tigen K; Gibson CM
    Catheter Cardiovasc Interv; 2012 Jan; 79(1):59-67. PubMed ID: 21523892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
    Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
    J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function.
    Pellicori P; Torromeo C; Barillà F; Mangieri E; Evangelista A; Truscelli G; Costanzo P; Hoye A; Wong K
    Cardiol J; 2013; 20(3):310-7. PubMed ID: 23788306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracoronary versus Intravenous eptifibatide during percutaneous coronary intervention for acute ST-segment elevation myocardial infarction; a randomized controlled trial.
    Sanati HR; Zahedmehr A; Firouzi A; Farrashi M; Amin K; Peighambari MM; Shakerian F; Kiani R
    Cardiovasc Interv Ther; 2017 Oct; 32(4):351-357. PubMed ID: 27534402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction.
    Esfandi A; Fotouhi M; Allami A; Ebrahimi M
    J Atheroscler Thromb; 2016; 23(4):465-76. PubMed ID: 26632161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
    Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
    Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
    Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK
    Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
    Fischell TA; Attia T; Rane S; Salman W
    J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.